Sonelokimab + Sonelokimab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioequivalence
Conditions
Relative Bioequivalence
Trial Timeline
Jun 5, 2025 → Nov 1, 2025
NCT ID
NCT06994936About Sonelokimab + Sonelokimab
Sonelokimab + Sonelokimab is a phase 1 stage product being developed by MoonLake Immunotherapeutics for Relative Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT06994936. Target conditions include Relative Bioequivalence.
What happened to similar drugs?
1 of 1 similar drugs in Relative Bioequivalence were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06994936 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioequivalence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABT-333 | AbbVie | Phase 1 | 29 |
| BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg | AstraZeneca | Phase 1 | 29 |
| D1400147 + D14000136 + D14000137 + Epanova® | AstraZeneca | Phase 1 | 29 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 40 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 23 |
| Tebipenem tablet form | Spero Therapeutics | Phase 1 | 19 |